GlaxoSmithKline News and Research

RSS

Neptune, Acasti completes preclinical program comparing CaPre with Lovaza

Neptune Technologies & Bioressources Inc. subsidiary, Acasti Pharma Inc., reports the completion of its preclinical program designed to compare the lipid management effects of Acasti's drug candidate CaPre versus prescription drug Lovaza.

25 Nov 2010

ViiV Healthcare awards $20 million to Idenix for GSK2248761 clinical milestone

Idenix Pharmaceuticals, Inc, a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the Company will receive a payment of $20 million from the ViiV Healthcare Company for the achievement of a clinical milestone relating to GSK2248761.

23 Nov 2010

Is the decade long flirtation with vaccines over?

In light of increasing competition, saturation of key vaccine sectors and a lack of innovative late-stage vaccine candidates, maintaining the strong growth of the last decade will be a major challenge for the vaccines industry suggests independent market analyst, Datamonitor.

22 Nov 2010

Convergence enters drug discovery collaboration with Selcia for chronic pain treatment

Convergence Pharmaceuticals Limited, the new company focused on the development of novel and high value analgesic medicines, and Selcia Limited, a contract research organisation, today are pleased to announce that they have entered into a drug discovery collaboration to identify and develop high quality candidate molecules for the treatment of chronic pain.

22 Nov 2010

COPD both a burden and a loss

Patients with Chronic Obstructive Pulmonary Disease, or COPD, revealed that they perceive their disease as both a burden they must deal with and as a loss they have experienced, according to recent in-home research conducted by GlaxoSmithKline. Patients participating in the research characterized their sense of loss as a combination of factors including loss of energy, loss of control, loss of independence and loss of their old self.

18 Nov 2010

COPD Biomarkers Qualification Consortium launched

The COPD Foundation announces the launch of an unprecedented collaborative effort to pool information on Chronic Obstructive Pulmonary Disease (COPD): the COPD Biomarkers Qualification Consortium (CBQC). The CBQC brings together government agencies, academic institutions and pharmaceutical companies that will share research data on COPD biomarkers—indicators of disease progression/severity.

18 Nov 2010

LFA encouraged by FDA Advisory Committee vote on BENLYSTA for autoimmune disease lupus

Today the U.S. Food and Drug Administration (FDA) Arthritis Advisory Committee voted overwhelmingly (13 to 2) to recommend BENLYSTA® for approval as a treatment for the autoimmune disease lupus. If FDA approved, BENLYSTA would become the first new treatment for lupus in 52 years. While today's vote is a positive step, the FDA still must make a final decision to approve BENLYSTA in the coming weeks.

17 Nov 2010

LRI pleased with FDA Advisory Committee's approval of Benlysta for lupus

The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations are pleased with the U.S. Food and Drug Administration (FDA) Advisory Committee's vote to recommend approval of Benlysta® for active systemic lupus erythematosus (SLE), offering patients new found hope for the first approved treatment option in more than 50 years.

17 Nov 2010

FDA Arthritis Advisory Committee recommends approval of BENLYSTA for SLE

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 13 to 2 to recommend that the FDA approve BENLYSTA (belimumab) for the treatment of autoantibody-positive patients with active systemic lupus erythematosus (SLE).

17 Nov 2010

NPR reports on dengue vaccine progress

NPR's Shots blog examines progress in the search for a vaccine to protect against the dengue virus. WHO estimates that 2.5 billion people worldwide are at risk of getting dengue, and most of them are in Asia and Latin America, the blog writes.

16 Nov 2010

Republicans take hard line, look for Democrat health law repeal allies

Republicans aren't softening their tough criticism of the health law even as they seek Democratic allies to join them in their bid to repeal the overhaul.

15 Nov 2010

Enrollment complete in Nabi's second NicVAX Phase III clinical trial for nicotine addiction

Nabi Biopharmaceuticals announced today that it has completed enrollment in the second Phase III clinical trial of NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational candidate vaccine being developed to treat nicotine addiction and prevent smoking relapse.

10 Nov 2010

Federal inspectors crack down on corrupt drug company executives

"Federal inspectors want to prevent drug-company executives from doing business with the U.S. government when their companies are convicted of Medicare fraud," The Washington Post reports. New guidelines from the Department of Health and Human Services say "executives can be barred from contracting with federal health programs when they knew, or if the inspector general concludes they should have known, about fraud at their firms."

10 Nov 2010

XenoPort third quarter net loss decreases to $19.9 million

XenoPort, Inc. announced today financial results for the third quarter and nine months ended September 30, 2010. Revenues for the third quarter were $0.4 million, compared to $0.4 million for the same period in 2009. Net loss for the third quarter was $19.9 million, compared to a net loss of $24.4 million for the same period in 2009.

8 Nov 2010

FDA reviews GSK's response to Complete Response letter for Horizant

GlaxoSmithKline and XenoPort, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review GSK's response to FDA's Complete Response letter for Horizant (gabapentin enacarbil) Extended-Release Tablets. Horizant is under review for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

8 Nov 2010

Melanoma drug breakthrough

Two latest drugs useful in melanoma are termed as the biggest breakthrough in the last five decades say cancer experts. These drugs are the first ones to be effective in advanced forms of the cancer.

5 Nov 2010

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.

4 Nov 2010

CaPre drug candidate effective in managing impaired glucose tolerance

Neptune Technologies & Bioressources Inc. subsidiary Acasti Pharma Inc. reports preclinical results showing that its leading drug candidate CaPre, performed significantly better than the currently marketed drug, Lovaza, at managing impaired glucose tolerance (IGT) a serious pre-diabetic state associated with increased risk of diabetes and heart disease.

4 Nov 2010

GSK's Revolade receives Japanese approval for treatment of chronic ITP

Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).

2 Nov 2010

Global Genes Project launches new campaign to create awareness about rare diseases

The Global Genes Project, a non-profit advocacy organization that aims to raise awareness about the prevalence of rare diseases worldwide, today launched the 7,000 Bracelets for Hope campaign. The 7,000 Bracelets for Hope campaign is designed to draw attention to an estimated 7,000 different chronic, life-threatening and fatal rare diseases and disorders affecting approximately 30 million Americans and millions more globally.

1 Nov 2010